Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	40.85B
Revenue (ttm)	8.62B
Net Income (ttm)	2.80B
Shares Out	3.31B
EPS (ttm)	0.85
PE Ratio	14.37
Forward PE	18.05
Dividend	$0.60 (4.79%)
Ex-Dividend Date	Dec 29, 2022

Volume	35,000
Open	12.68
Previous Close	12.41
Day's Range	12.25 - 12.68
52-Week Range	10.99 - 17.49
Beta	0.51
Analysts	Buy
Price Target	15.65 (+24.34%)
Earnings Date	n/a

About CHGCY

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,664
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2021, CHGCY's revenue was 999.76 billion, an increase of 27.04% compared to the previous year's 786.95 billion. Earnings were 303.00 billion, an increase of 41.10%.

Financial numbers in JPY

Analyst Forecast

According to 16 analysts, the average rating for CHGCY stock is "Buy." The 12-month stock price forecast is $15.65, which is an increase of 24.34% from the latest price.

Price Target

$15.65

(24.34% upside)

Analyst Consensus: Buy